Lexeo Therapeutics joins small class of 2023 biotech IPOs in $100M Nasdaq listing
Lexeo Therapeutics will begin trading on the Nasdaq on Friday morning via a $100 million initial public offering.
The cardiac and Alzheimer’s gene therapy biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.